한국군에서의 한타박스^® (HFRS국내백신)의 효용성에 대한 연구 = The clinical effectiveness of Hantavax^Ⓡ in Korean Military Soldiers

다국어 초록 (Multilingual Abstract)

Introduction: Hemorrhagic fever with renal syndrome (HFRS), although its incidence is decreasing, reveals severe renal clinical course and high mortality. Military croups have many outdoor activities, so soldiers cannot avoid to exposure of Hantan virus in epidemic area in Korea. Therefore, soldiers in epidemic area were scheculed to vaccinate HantavaxⓇ which is intoxicated vaccine. this study aims that HantavaxⓇ can influence with the clinical course of HFRS.
Methods: Twenty nine male patients ,who were diagnosed HFRS in the Armed Forces Capital Hospital, were retrospectively enrolled from March 2009 to July 2010. Patients have positive results in Hantan virus antibody using with rapid chromatography test and they have no history of vaccination within three month recently. Nephrology specialist diagnosed the HFRS in patient and enrolled them in study group. All patients were confirmed the vaccination history which is based on public record of his croup, not his memory's. Researchers could check patient's precise vaccination history, the day and the times. We classified patients by non-vaccination patients (group 1) and vaccination patient (group 2) and investigated clinical course of both groups.
Results: Eleven patients (37.9%) had been vaccinated previously and eighteen patient had not had vaccination. None of study patients was died. six patients of group 1 must have been dialysis treatment during acute status and none of group 2 were not dialysis treatment. Eleven patients of group 1 experienced oliguria, but only one patient of group 2 have oliguric phase. These clinical course shows stastically different from group 1 and group 2(p=0.032, p=0.011). These results are announced that vaccination might have protective effect against the HFRS. Admission day, titer of antibody, hematologic and chemical test were not different among two groups.
Conclusion: Vaccination group of HantavaxⓇ in patients had better clinical course than non-vaccination group. Additional study should be needed for evaluating of renal protective effect of HantavaxⓇ.